Article
Urology & Nephrology
Alberto Martini, Giuseppe Fallara, Francesco Pellegrino, Giuseppe Ottone Cirulli, Alessandro Larcher, Andrea Necchi, Francesco Montorsi, Umberto Capitanio
Summary: The treatment landscape for renal cell carcinoma is rapidly evolving, with nine studies currently evaluating the role of immunotherapy in the neoadjuvant setting and four studies in the adjuvant setting.
WORLD JOURNAL OF UROLOGY
(2021)
Letter
Medicine, General & Internal
Aparna Sharma, Ranjit K. Sahoo, Atul Batra, Archie Bleyer, Toni K. Choueiri, Thomas Powles
Summary: Adding adjuvant pembrolizumab after nephrectomy can significantly improve disease-free survival in patients with renal-cell carcinoma, but there are concerns regarding the arbitrary duration of 12 months of adjuvant treatment. Many patients discontinued treatment due to adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jose A. Karam, Pavlos Msaouel, Cara L. Haymaker, Surena F. Matin, Matthew T. Campbell, Amado J. Zurita, Amishi Y. Shah, Ignacio I. Wistuba, Enrica Marmonti, Dzifa Y. Duose, Edwin R. Parra, Luisa Maren Solis Soto, Caddie Laberiano-Fernandez, Marisa Lozano, Alice Abraham, Max Hallin, Curtis D. Chin, Peter Olson, Hirak Der-Torossian, Xiaohong Yan, Nizar M. Tannir, Christopher G. Wood
Summary: In patients with locally advanced clear cell renal cell carcinoma (ccRCC), neoadjuvant sitravatinib and nivolumab has shown promising results in terms of safety and radiological efficacy.
NATURE COMMUNICATIONS
(2023)
Article
Urology & Nephrology
Maria I. Carlo, Kyrollis Attalla, Yousef Mazaheri, Sounak Gupta, Onur Yildirim, Samuel J. Murray, Devyn T. Coskey, Ritesh Kotecha, Chung-Han Lee, Darren R. Feldman, Paul Russo, Sujata Patil, Robert J. Motzer, Jonathan A. Coleman, Jeremy C. Durack, Ying-Bei Chen, Oguz Akin, A. Ari Hakimi, Martin H. Voss
Summary: This study evaluated the outcomes of localized kidney cancer patients who received immunotherapy prior to surgery. It found that this approach was safe and feasible, without significant surgical delays and with an expected rate of immune-related adverse events.
Article
Medicine, General & Internal
T. K. Choueiri, P. Tomczak, S. H. Park, B. Venugopal, T. Ferguson, Y. -H. Chang, J. Hajek, S. N. Symeonides, J. L. Lee, N. Sarwar, A. Thiery-Vuillemin, M. Gross-Goupil, M. Mahave, N. B. Haas, P. Sawrycki, H. Gurney, C. Chevreau, B. Melichar, E. Kopyltsov, A. Alva, J. M. Burke, G. Doshi, D. Topart, S. Oudard, H. Hammers, H. Kitamura, J. Bedke, R. F. Perini, P. Zhang, K. Imai, J. Willemann-Rogerio, D. I. Quinn, T. Powles
Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Urology & Nephrology
Robert J. Motzer, Paul Russo, Naomi Haas, Christian Doehn, Frede Donskov, Marine Gross-Goupil, Sergei Varlamov, Evgeny Kopyltsov, Jae Lyun Lee, Ho Yeong Lim, Bohuslav Melichar, Milada Zemanova, Brian Rini, Toni K. Choueirim, Lori Wood, M. Neil Reaume, Arnulf Stenzl, Simon Chowdhury, Ray McDermott, Agnieszka Michael, Miguel Izquierdo, Paola Aimone, Hong Zhang, Cora N. Sternberg
Summary: The PROTECT study found no significant difference in overall survival for patients with locally advanced RCC at high risk of relapse after nephrectomy who received adjuvant therapy with pazopanib or placebo, indicating that pazopanib is not recommended as adjuvant therapy following resection of locally advanced RCC.
Article
Oncology
Hanzhi Dong, Yuan Cao, Yan Jian, Jun Lei, Weimin Zhou, Xiaoling Yu, Xiquan Zhang, Zhiqiang Peng, Zhe Sun
Summary: This study analyzed the impact of nephrectomy on survival in patients with metastatic renal cell carcinoma who received immune-targeted therapy. The results showed that patients who underwent nephrectomy achieved survival benefits, and nephrectomy, clear cell carcinoma, and oligo-organ metastasis were found to be favorable independent prognostic factors.
Article
Oncology
Michael A. Gorin, Hiten D. Patel, Steven P. Rowe, Noah M. Hahn, Hans J. Hammers, Alice Pons, Bruce J. Trock, Phillip M. Pierorazio, Thomas R. Nirschl, Daniela C. Salles, Julie E. Stein, Tamara L. Lotan, Janis M. Taube, Charles G. Drake, Mohamad E. Allaf
Summary: In this study, the safety and tolerability of preoperative administration of three doses of the immune checkpoint inhibitor nivolumab in patients with clinically localized high-risk renal cell carcinoma were evaluated. The study demonstrated the safety of this approach and found that a subset of patients may have features of an immune-related pathologic response.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Urology & Nephrology
Yong Zhang, Tingkun Wu, Jingjing Xie, Liqun Yan, Xiuli Guo, Weijia Xu, Liping Wang
Summary: Radical nephrectomy remains the standard treatment for renal cell carcinoma, but the increased risk of chronic kidney disease in patients with concomitant metabolic syndrome (MetS) should be considered. Monitoring renal function after surgery is crucial, especially for patients with MetS.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2021)
Article
Oncology
Jacob J. Adashek, Yumeng Zhang, William Paul Skelton, Alyssa Bilotta, Jad Chahoud, Logan Zemp, Jiannong Li, Jasreman Dhillon, Brandon Manley, Philippe E. Spiess
Summary: The presence of sarcomatoid features within tumor histology, regardless of clear cell or non-clear cell RCC, is associated with significantly poor prognosis. Patients with sRCC have shorter overall survival compared to those without sarcomatoid features, and even patients with 10% or less sarcomatoid features do not benefit from cytoreductive nephrectomy. The role of radiomics and pre-operative biopsies may play a significant role in improving outcomes for this patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Liliana Eleonora Semenescu, Ligia Gabriela Tataranu, Anica Dricu, Gheorghe Vasile Ciubotaru, Mugurel Petrinel Radoi, Silvia Mara Baez Rodriguez, Amira Kamel
Summary: Despite the era of targeted therapies, neurosurgery still plays an important role in the treatment of brain metastases from renal cell carcinoma (BM RCC). This study found that nephrectomy, systemic therapy, and a single brain metastasis were associated with improved survival rates. Additionally, higher levels of hemoglobin were correlated with an increased number of brain metastases.
Article
Oncology
Yang Liu, Xinyue Zhang, Huali Ma, Li Tian, Lixin Mai, Wen Long, Zhiling Zhang, Hui Han, Fangjian Zhou, Pei Dong, Liru He
Summary: This study compared different treatment modalities and found that local therapy (surgery or SBRT) was more effective than systemic therapy alone in delaying disease progression. Additionally, the study found that SBRT was safe and effective for locally recurrent RCC.
Article
Urology & Nephrology
Ziad Bakouny, Talal El Zarif, Shaan Dudani, J. Connor Wells, Chun Loo Gan, Frede Donskov, Julia Shapiro, Ian D. Davis, Francis Parnis, Praful Ravi, John A. Steinharter, Neeraj Agarwal, Ajjai Alva, Lori Wood, Anil Kapoor, Jose M. Ruiz Morales, Christian Kollmannsberger, Benoit Beuselinck, Wanling Xie, Daniel Y. C. Heng, Toni K. Choueiri
Summary: This study found that upfront cytoreductive nephrectomy (CN) is associated with improved clinical outcomes and overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors or targeted therapy. This suggests that upfront CN still has a significant role for selected patients in the era of immune checkpoint inhibitors.
Article
Oncology
Cora N. Sternberg, Ian D. Davis, Jozef Mardiak, Cezary Szczylik, Eunsik Lee, John Wagstaff, Carlos H. Barrios, Pamela Salman, Oleg A. Gladkov, Alexander Kavina, Juan J. Zarba, Mei Chen, Lauren McCann, Lini Pandite, Debasish F. Roychowdhury, Robert E. Hawkins
Summary: This study evaluated the efficacy and safety of Pazopanib in the treatment of advanced renal cell carcinoma. The results showed significant improvement in progression-free survival and tumor response with Pazopanib compared to placebo.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Andrew W. Silagy, Ritesh R. Kotecha, Stanley Weng, Arturo Holmes, Nirmish Singla, Roy Mano, Kyrollis Attalla, Kate L. Weiss, Renzo G. DiNatale, Sujata Patil, Jonathan A. Coleman, Robert J. Motzer, Paul Russo, Martin H. Voss, A. Ari Hakimi
Summary: The systemic responses to cytoreductive nephrectomy in the management of metastatic renal cell carcinoma are variable. Patients undergoing surgery had fewer modifiable IMDC risk factors, fewer metastases, and higher proportions of clear cell histology. An increase in IMDC risk factors at 6 weeks and 6 months post-surgery was associated with adverse overall survival.
Article
Oncology
Kevin B. Ginsburg, Marshall Strother, Jared P. Schober, Alberto Andres Castro Bigalli, Karen Ruth, David YT. Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Robert G. Uzzo, Andres F. Correa, Alexander Kutikov
Summary: A study compared the renal function outcomes of patients with oncocytomas undergoing active surveillance and partial nephrectomy, and found no significant difference between the two groups.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Letter
Oncology
Laura Bukavina, Mohit Sindhani, Shreyas S. Joshi, Elizabeth Plimack, Andres Correa, Nicole Uzzo, Alexander Kutikov, Robert Uzzo
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Antoin Douglawi, Alireza Ghoreifi, Umberto Carbonara, Wesley Yip, Robert G. Uzzo, Vitaly Margulis, Matteo Ferro, Ottavio De Cobelli, Zhenjie Wu, Giuseppe Simone, Riccardo Mastroianni, Koon H. Rha, Daniel D. Eun, Adam C. Reese, James R. Porter, Ithaar Derweesh, Reza Mehrazin, Giuseppe Rosiello, Riccardo Tellini, Marcus Jamil, Alexander Kenigsberg, Jason M. Farrow, William P. Schrock, Giovanni Cacciamani, Abhishek Srivastava, Amit S. Bhattu, Alexandre Mottrie, Mark L. Gonzalgo, Chandru P. Sundaram, Firas Abdollah, Andrea Minervini, Riccardo Autorino, Hooman Djaladat
Summary: This study retrospectively analyzed data of UTUC patients who underwent RNU and found that VH was associated with increased risk of metastasis and death.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Oncology
Laura Bukavina, Spencer Bell, Vignesh T. Packiam, Marc Smaldone, Philip Abbosh, Robert Uzzo, Alexander Kutikov, Andres F. Correa, Diana E. Magee
Summary: This study evaluated the cost effectiveness of BCG compared to sequential gemcitabine-docetaxel in high-risk NMIBC patients. The results showed that gemcitabine-docetaxel had similar effectiveness but lower cost than BCG, making it a potential alternative as a first-line intravesical therapy.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Marshall Strother, Robert N. Uzzo, Elizabeth Handorf, Robert G. Uzzo
Summary: The study aimed to validate the overflowing beer sign (OBS) for distinguishing between lipid-poor angiomyolipoma (AML) and renal cell carcinoma, and to determine whether it improves the detection of lipid-poor AML when added to the angular interface sign. The results showed that both OBS and angular interface sign were strongly associated with AML and had high specificity in the lipid-poor population. Using both signs together increased the sensitivity of AML detection without significantly reducing specificity.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Oncology
Laura Bukavina, Ilaha Isali, Rashida Ginwala, Mohit Sindhani, Adam Calaway, Diana Magee, Benjamin Miron, Andres Correa, Alexander Kutikov, Matthew Zibelman, Mahmoud Ghannoum, Mauricio Retuerto, Lee Ponsky, Sarah Markt, Robert Uzzo, Philip Abbosh
Summary: This study aimed to compare the urine microbiome of bladder cancer patients with healthy controls using a machine learning algorithm and identified some bacteria associated with bladder cancer. The results showed that the composition differences of urine microbiome were mainly related to geographical location, but also associated with sample collection methodology. After removing contaminants, several key bacteria more likely to be found in the urine of bladder cancer patients were identified, all of which have the ability to break down tobacco carcinogens.
EUROPEAN UROLOGY ONCOLOGY
(2023)
Article
Urology & Nephrology
Jared P. Schober, Kevin B. Ginsburg, Alexander Kutikov, Eric Y. Cho, Matt Loecher, David Strauss, Alberto Andres Castro Bigalli, Elizabeth Handorf, Mengying Deng, Jordan Anaokar, David Y. T. Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Andres F. Correa, Robert G. Uzzo, Marshall Strother
Summary: This study aimed to evaluate whether a simple point-of-care measurement system could be used to replace nuclear medicine renal scintigraphy (NMRS) in predicting estimated glomerular filtration rate (eGFR) after nephrectomy. The results showed that the point-of-care tool (RENAL-MS) performed equally well as NMRS in predicting postoperative eGFR and de novo Stage 3 chronic kidney disease (CKD), suggesting that NMRS may not be necessary in this setting.
Article
Urology & Nephrology
Deepak K. Pruthi, Gregor Miller, Donna P. Ankerst, Matthias Neumair, Umberto Capitanio, Andres F. Correa, Brian R. Lane, Eduard Roussel, Thomas B. Mcgregor, Ithaar H. Derweesh, Mauricio Cordeiro, Phillip M. Pierorazio, Carlos Calvo, Hai Bi, Sabrina L. Noyes, Margaret Meagher, Alexander Kutikov, Robert G. Uzzo, Hendrik Van Poppel, Alessandro Larcher, Francesco Montorsi, Michael W. Kattan, Dharam Kaushik, Michael A. Liss
Summary: This study aimed to investigate whether clinical risk factors and morphometric features on preoperative imaging can predict pathological upstaging in cT1 renal cell carcinoma patients. Through a retrospective study, we found that increasing preoperative tumor size, increasing age, diabetes, higher BMI, and male sex were associated with pathological upstaging. Additionally, hilar tumors were more likely to be upstaged.
JOURNAL OF UROLOGY
(2023)
Article
Medicine, General & Internal
Christopher W. Ryan, Catherine M. Tangen, Elisabeth Heath, Mark N. Stein, Maxwell Meng, Ajjai S. Alva, Sumanta K. Pal, Igor Puzanov, Joseph Clark, Toni K. Choueiri, Neeraj Agarwal, Robert G. Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Ian M. Thompson Jr, Primo N. Lara Jr
Summary: Postoperative administration of everolimus did not show improvement in recurrence-free survival compared to placebo for renal cell carcinoma patients at high risk of recurrence after nephrectomy. These results do not provide support for the adjuvant use of everolimus in the treatment of renal cell carcinoma following surgery.
Meeting Abstract
Urology & Nephrology
Diana Magee, Kevin Ginsburg, Jared Schober, Laura Bukavina, Spencer Bell, Elizabeth Handorf, Alexander Kutikov, Robert Uzzo, Andres Correa
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Spencer H. Bell, Emma Helstrom, Eric M. Horwitz, Mark A. Hallman, Jessica Wong, Robert Uzzo, Alexander Kutikov, David Chen, Richard E. Greenberg, Marc C. Smaldone, Rosalia Viterbo, Nicole Uzzo, Andres F. Correa
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Laura Bukavina, Spencer Bell, Vignesh Packiam, Marc Smaldone, Phillip Abosh, Robert Uzzo, Alexander Kutikov, Andres Correa, Diana Magee
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Laura Bukavina, Imran Safder, Spencer Bell, Daniel Geynishman, Ilaha Isali, Daniel Ranti, John Sfakianos, Henkel Valentine, Adam Calaway, Alexander Kutikov, Andres Correa, Robert Uzzo, Lee Ponsky, Philip Abbosh
JOURNAL OF UROLOGY
(2023)
Meeting Abstract
Urology & Nephrology
Clara Cerrato, Margaret F. Meagher, Riccardo Autorino, Giuseppe Simone, Bo Yang, Robert Uzzo, Francesco Porpiglia, Umberto Capitanio, James Porter, Alp T. Beksac, Mimi Nguyen, Savio D. Pandolfo, Kevin Hakimi, Luke Wang, Andrea Minervini, Clayton Lau, Monish Aron, Daniel Eun, Alexandre Mottrie, Carmen Mir, Chandru Sundaram, Alessandro Antonelli, Jihad Kaouk, Ithaar H. Derweesh
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Clara Cerrato, Devin Patel, Riccardo Autorino, Giuseppe Simone, Bo Yang, Robert Uzzo, Francesco Porpiglia, Umberto Capitanio, James Porter, Alp Tuna Beksac, Andrea Minervini, Alessandro Antonelli, Maria Angela Cerruto, Clayton Lau, Akbar Ashrafi, Daniel Eun, Alexandre Mottrie, Carmen Mir, Margaret F. Meagher, Dhruv Puri, Mimi Nguyen, Sohail Dhanji, Franklin Liu, Savio D. Pandolfo, Alexander Kutikov, Francesco Montorsi, Inderbir S. Gill, Chandru Sundaram, Jihad Kaouk, Ithaar H. Derweesh
Summary: This study compares the outcomes of robotic-assisted partial nephrectomy (RAPN) and minimally invasive radical nephrectomy (MIS-RN) for complex renal masses (CRM). The results indicate that RAPN is not associated with increased risk of complications or worsened oncological outcomes compared to MIS-RN, and may be preferred when clinically indicated.
WORLD JOURNAL OF UROLOGY
(2023)